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ABSTRACT
MHC class II presented peptides can be derived from both exogenous
(extracellular) and endogenous (biosynthesized) sources of antigen. Although several
endogenous antigen processing pathways have been reported, little is known about their
relative contributions to global CD4+ T cell responses against complex antigens. Using
influenza for this purpose, we assessed the role of macroautophagy, a process in which
cytosolic proteins are delivered to the lysosome by de novo vesicle formation and
membrane fusion. Influenza infection triggered productive macroautophagy and
autophagy-dependent presentation was readily observed with model antigens that
naturally traffic to the autophagosome. Furthermore, treatments that enhance or inhibit
macroautophagy modulated the level of presentation from these model antigens.
However, validated ELISpot assays of influenza-specific CD4+ T cells from infected

mice using a variety of antigen presenting cells, including primary dendritic cells,
revealed no detectable macroautophagy-dependent component. In contrast, the
contribution of proteasome-dependent endogenous antigen processing to the global
influenza CD4+ response was readily appreciated. The contribution of macroautophagy to
the MHC class II restricted response may vary depending upon the pathogen.

INTRODUCTION
Activation of CD4+ T cells depends upon their recognition of peptides (epitopes)
associated with major histocompatibility class (MHC) class II molecules. Conventionally,
peptide generation involves the degradation of exogenous (extracellular) antigens in the
endosomal network by multiple mechanisms including unfolding, reduction and
proteolytic degradation. It is now clear that epitopes derived from endogenous antigens
(synthesized by the cell) can also be presented on MHC class II molecules (12, 22, 24,
38, 49, 50, 60, 66). Indeed, endogenous antigen expression appears to be an absolute
requirement for the presentation of some epitopes. For example, UV inactivation of
A/PR8/34 influenza virus (PR8) or treatment of infected antigen-presenting cells (APCs)
with protein synthesis inhibitors prevents presentation of the NA79 epitope (12). Similar

observations have been made for an epitope derived from influenza matrix protein 1 (24)
and an epitope derived from the MHC class I H2-Ld molecule (39).
Numerous studies have now demonstrated that endogenous antigens can gain
access to MHC class II loading compartments via a variety of intracellular pathways (4,
38, 49, 57, 66, 67). Perhaps the most straightforward route is autophagy, in which
cytosolic proteins are delivered to the lysosome via several different mechanisms.
Chaperone-mediated autophagy results in delivery of cytosolic proteins directly to the
lysosome based upon the recognition of a “KFERQ” pentapeptide motif within the target
protein, and was shown to be responsible for the presentation of an epitope derived from
glutamate decarboxylase (72). Although 30 % of cytosolic proteins contain this motif
(70), CMA has not yet been implicated in the class II-restricted response to an infectious
agent. Macroautophagy is characterized by the formation of a double membrane structure
that engulfs portions of the cytosol including proteins, organelles and/or invading
pathogens. The resultant autophagosomes undergo membrane fusion with lysosomes and
rapid degradation of the contents ensues (18). Macroautophagic vesicles fuse
continuously with class II positive compartments (60) and several epitopes have been
shown to depend upon macroautophagy for class II-restricted presentation, including
those derived from the C5 protein of the complement pathway (2), neomycin
phosphotransferase (45, 53) and the Epstein Barr virus Nuclear Antigen 1 (EBNA-1) (35,
50). Interestingly, EBNA-1 contains two class II-restricted endogenous epitopes that are
not autophagy dependent, suggesting that this protein can be processed via more than one
pathway (35). Other studies of macroautophagy in antigen processing have employed
engineered model antigens in which a well-defined epitope is affixed to a protein that

naturally localizes to the autophagosome. For example, autophagy-dependent
presentation was demonstrated for an influenza matrix protein 1 derived epitope fused to
the LC3B protein that is involved in autophagosome formation (60).
While a contribution by macroautophagy to class II processing is intuitively
appealing, several considerations complicate the picture: 1) In many cases the aggressive
proteolysis associated with autophagy may be counterproductive for antigen processing.
Presentation of many epitopes is diminished or ablated with elevated endosomal
proteolysis (6, 58). Likewise, it has been reported that dendritic cells with reduced
endosomal proteolytic activity are more efficient antigen presenters (6, 58). 2) Results
that suggest a role for autophagy may have alternative explanations. For example,
autophagy was implicated in the class II restricted presentation of antigens derived from
nuclear and cytosolic proteins (8) due to the positive effects of serum starvation but this
condition also enhances proteasomal activity (14). In addition, gene ablation of a key
autophagy component has been reported to impact not just autophagy, but the
presentation of exogenous antigens as well (1, 34). 3) Some autophagy substrates may be
atypical. For example, EBNA-1 is unusual in containing a Glycine-Alanine (Gly-Ala)
repeat region that appears to be involved in immune evasion (36, 37) and also renders the
protein prone to aggregation (19, 40) thereby increasing its susceptibility to autophagy
(52, 68). 4) Finally, in studying the presentation of class II-restricted epitopes from the
influenza neuraminidase and hemagglutinin (HA) glycoproteins, our laboratory has
identified an endogenous pathway that depends upon the multicatalytic proteasome, the
macromolecular complex that is responsible for most protein turnover within the cytosol
and nucleus (13, 17, 20). Remarkably, ELISpot assays revealed that 30-40% of the total

MHC class II restricted response to influenza is specific for proteasome-dependent
epitopes (66), a fraction that, when added to the contribution of exogenous processing,
may largely discount other processing pathways. Thus, elucidating the relative roles of
various processing pathways will require a more global approach.
Here we have taken such a global approach in assessing the CD4+ T cell responses
to influenza virus infection. Although influenza infection activates functional autophagy
and we were able to detect autophagy dependent presentation with engineered processing
substrates, we could discern no significant contribution of this pathway to the CD4+ T cell
response.

MATERIALS AND METHODS
Cells, plasmids and viruses. L929 fibroblasts stably expressing the H2d restricted MHC
class II molecule I-Ed (L-IEd) or B6 fibroblasts stably expressing I-Ed and CIITA (B6IEd) were cultured in DMEM (Mediatech Inc, Manassas, Va) supplemented with 10%
fetal calf serum (Invitrogen, Carlsbad, CA) and 1x 2-mercaptoethanol (Invitrogen) at 9%
CO2. Atg5 wild type or KO fibroblasts were cultured in DMEM supplemented with 10%
fetal calf serum 1x non-essential amino acids and maintained at 9% CO2 (fibroblasts were
a kind gift of Dr. David Leib, Dartmouth Medical School). The A20 B cell lymphoma
cell line was maintained in IMDM with 10% fetal calf serum and the Raw264.7 cell line
was maintained in DMEM with 10% fetal calf serum at 9% CO2. A lacZ a T cell
hybridoma specific for the Site-1 epitope of influenza hemagglutinin (62, 66) was used in
MUG assays and passaged in RPMI-1640 (Mediatech, Inc) supplemented with 10% fetal
calf serum and 1x 2-mercaptoethanol and maintained at 6% CO2.
For plasmid generation, the S1 epitope was inserted at the C terminus of
Neomycin phosphotransferase or the N terminus of LC3B by PCR using primers that
encoded for the S1 epitope at the indicated position. The PCR product was inserted into
the pGEM T Easy vector (Thermo Fisher Scientific) and subsequently cloned into the
pMSCV vector (generous gift of Dr. Jianke Zhang, Thomas Jefferson University). All
DNA constructs were verified by sequencing.
The influenza viruses A/PR/8/34 (PR8; H1N1), A/Japan/305/57 (Jap; H2N2), and
B/Lee/40 (B/Lee) were grown as previously described (66). For experiments involving
UV virus, live PR8 was diluted in PBS and subjected to UV light for 10 minutes with
gentle shaking. Inactivation of the virus was confirmed by staining fibroblasts pulsed

with UV PR8 virus for influenza proteins via flow cytometry. Viral titers were
determined using chicken red blood cells and were expressed in hemagglutinin units
(HAU). Adenovirus expressing S1LC3 (Ad-S1LC3) was generated by cloning the S1LC3
construct into the pENTR4 entry vector (Invitrogen), followed by subcloning into
pAd/CMV/V5-DEST (Invitrogen). Virus was produced in 293A cells (Invitrogen) by
transfection with linearized S1LC3-pAd/CMV/V5, followed by expansion and
purification with the Adeno-X Purification Kit according to manufacturer’s
recommendations (BD Biosciences, San Jose CA).

Mice. Female BALB/c (H-2d) and CB6F1 (H-2bxd) mice aged 6-8 weeks were obtained
from Jackson Laboratories (Bar Harbor, ME) and maintained at Thomas Jefferson
University (Philadelphia PA). Mice were primed intraperitoneally with 100HAU of
infectious PR8 or B-Lee diluted in cold PBS or intranasally with 0.1, 0.01, or
0.0001HAU of infectious PR8 in cold PBS. At least 10 days after priming, mice were
euthanized using CO2 and spleens were harvested. CD4+ T cells were purified using the
Dynal magnetic bead negative selection kit according to manufactures instruction
(Invitrogen) and the purified cells were subsequently used in all ELISpot experiments.
All experimental procedures involving mice were approved by the Institutional Animal
Care and Use Committee at Thomas Jefferson University.

Generation and Retroviral Transduction of Bone Marrow Derived Primary
Dendritic Cells. Bone marrow was isolated from the femurs and tibias of naïve female
BALB/c or CB6F1 mice as previously described (66). Bone marrow was plated in 10cm

culture dishes at 2x106 cells/plate in a final volume of 10mL of RPMI supplemented with
10%FCS, 1x Penicillin/Streptomycin, 1x L-glutamine, 1x 2ME and GM-CSF (10ng/mL).
48 hours later the cells were harvested, counted and plated in 24 well plates at 1x106 cells
per well. shRNA directed against Atg7 was designed using RNAiCODEX and cloned
into the LMP retroviral vector encoding GFP under an IRES promoter (OpenBiosystems,
Thermo Fischer Scientific). Retrovirus encoding Atg7shRNA or an empty LMP vector
was overlaid onto the primary cells and the cells were spun at 1000g for two hours. After
the transduction, fresh growth medium was added to the cells. 48-72 hours after
transduction (66) the cells were harvested and sorted for GFP expression for use in
ELISpot assays. As in other knockdown experiments, reduction of Atg7 was confirmed
by western blotting.

siRNA Transfections siRNA against Atg7, Rpt2 or a scrambled control were obtained
from Ambion (Applied Biosystems, Austin TX). L-IEd fibroblasts were transfected with
indicated siRNAs using Amaxa Nucleofection kit V (Lonza, Allendale, NJ) once (48
hours before assay) or twice in a four day period (#1 at day 0; #2 at day 2). B6-IEd
fibroblasts were transfected with the indicated siRNAs three days prior to assays using
RNAiMAX transfection reagent (Invitrogen). A 20 and Raw264.7 cell lines were
transfected with siRNA using Amaxa Nucleofection Kit V (Lonza) 48 hours before use
(for A20s) or twice within a 48 hour period (for RAW264.7). For the final 24 hours of
culture, the Raw264.7 treated with IFN-γ to upregulate class II machinery. For siRNA
knockdown of the autophagy construct S1LC3, B6-IEd fibroblasts stably expressing

S1LC3 were transfected twice within a three day period in order to ensure complete
knockdown of preexisting S1pMHC complexes.

Assessment of autophagy induction and knockdown. To examine induction of
autophagy after influenza virus infection, L-IEd or B6-IEd fibroblasts were infected with
PR8 (4-50 HAU/106 cells) for 30 minutes at 37oC in PBS/0.1% BSA. At the indicated
time points or after an overnight (~16 hours) culture, the cells were trypsinized, washed,
and lysed in lysis buffer (100mM NaCl, 100mM Tris pH 8.0, 1% Triton-X)in the
presence of HALT protease inhibitor cocktail (Thermo Fischer Scientific) for 15 minutes
on ice. Samples were centrifuged for 15 minutes at 13,000g, 4oC to remove debris and
protein concentrations were determined by BCA assay (Thermo Fisher Scientific). Equal
amounts of protein were loaded onto a 12% SDS gel, subjected to electrophoresis and
transferred to a nitrocellulose membrane (GE Healthcare, Piscataway, NJ) membrane for
blotting. Anti-LC3b, Anti-Atg7, and anti-actin were obtained from Sigma Aldrich (St
Louis, MO).

In vitro antigen presentation assays. B6-IEd fibroblasts were transiently transfected
with the indicated constructs using GeneJuice (EMD Biosciences, Gibbstown, NJ).
Twenty four hours after transfection, autophagy was induced by treating cells with
200nM rapamycin (EMD Biosciences) overnight. Cells were harvested, fixed with 0.05%
PFA (Electron Microscopy Services, Hatfield PA) in 1xHBSS (Thermo Fisher Scientific)
for 15 minutes at room temperature, washed extensively and cultured overnight with S1 T
hybridomas. T cell activation was assessed by measuring beta-galactosidase activity

using the fluorescent substrate 4-methylumbelliferyl ß-D-glucuronide (MUG) with the
amount of fluorescence being directly proportional to T cell activation (56, 62).
For chemical inhibition, the autophagy construct S1LC3 was transfected into B6IEd as described above. Twenty four hours later the cells were washed in PBS, acid
washed to remove existing pMHC-II complexes from the surface, washed extensively
and cultured overnight in the presentence of 3MA (Sigma Aldrich) or wortmannin (EMD
Biosciences). Cells were harvested and cultured for 6 hours with S1 T hybridomas in a
MUG assay. For siRNA mediated inhibition, the autophagy construct S1LC3 was stably
transfected into B6-IEd and siRNA was transfected as described above. Cells were
harvested and cultured with S1 T hybridomas overnight in a MUG assay.

ELISpots. L-IEd or B6-IEd fibroblasts, A20 B cell lymphoma, RAW264.7 macrophages
or primary BMDCs were transfected/transduced with the indicated siRNAs or shRNAs.
After the optimal time periods for maximal knockdown, the cells were harvested and
pulsed with infectious PR8 or UV inactivated PR8 for 30-60 minutes at 37oC in
PBS/0.1%BSA. Cells were washed and cultured overnight with purified CD4+ T cells
from the spleens of PR8 primed mice in an IFN-γ ELISpot assay. The next day the assay
was developed according to manufactures instructions (BD Biosciences). For
experiments involving AdenoS1LC3, L-IEd fibroblasts were transfected with indicated
siRNAs. Six hours after the second transfection, media was changed and the cells were
infected with Ad-S1LC3 (3x108 IFU/0.2x106 cells). 36-48 hours after infection, the
infected L-IEd fibroblasts were harvested and cultured overnight with purified CD4+ T
cells from a PR8 primed mouse in an IFN-γ ELISpot assay. The AdS1LC3 infected L-

IEd fibroblasts were also cultured overnight with S1 T hybridomas in a MUG assay. For
experiments involving epoxomicin, cells were pretreated with 0.5uM epoxomicin (Enzo
Life Sciences, Plymouth Meeting, PA) for 15 minutes prior to infection.

Statistical Analysis. Statistics were calculated using a paired Student t Test. p values
<0.05 were considered significant.

RESULTS
Influenza infection induces functional macroautophagy. Autophagy can be induced by
a variety of viral and bacterial infections (26, 30, 48). Two recent publications reported
that influenza virus infection can induce autophagy (15, 73), however one of these
indicated that the process is incomplete due to inhibition of vesicular fusion (15). To
explore autophagy induction and maturation in our system, L929 fibroblasts stably
transfected with the I-Edα and I-Edβ genes (L-IEd) or B6 fibroblasts stably transduced
with I-Edα and I-Edβ (B6-IEd) were infected with influenza virus A/PR/8/34 (PR8). As a
positive control, the cell lines were treated with the known autophagy inducer rapamycin
(47). Autophagy induction was then assessed by measuring the conversion of LC3-I to
LC3-II via western blot (41, 55). In both fibroblast lines, PR8 infection induced
conversion of LC3-I to LC3-II in a time-dependent manner beginning at 8 hours after
infection (Fig. 1a). Treatment of infected cells with Bafilomycin A1, which neutralizes
endosomal vesicles, thereby preventing turnover of converted LC3, accentuated this
effect (Fig. 1b) indicating that LC3 conversion is not an artifact of increased LC3
synthesis. Inhibition of autophagy via siRNA targeting Atg7, a ubiquitin ligase-like
protein essential for autophagosome expansion, resulted in decreased LC3-II
accumulation compared to control cells in response to influenza virus infection (Fig. 1c).
Atg7 siRNA had a similar impact when rapamycin was used to induce autophagy (data
not shown).
To determine whether macroautophagy progressed to maturation we generated
B6-IEd fibroblasts that stably express a GFP-LC3 fusion construct (42). Autophagy
induction via PR8 infection in B6-IEd-GFP-LC3 cells resulted in a significant decrease in

GFP fluorescence (Fig. 2a left panel), reflecting successful fusion of the autophagosome
and destruction of the contents (61). Reduction in fluorescence was not observed in cells
expressing unconjugated GFP (Fig. 2a right panel). Furthermore, chemical inhibition of
autophagy via wortmannin prevented the reduction of GFP levels after influenza virus
infection (Fig. 2b) as well as the accumulation of endogenous LC3-II (Fig. 2c). In
addition, PR8 infection of L-IEd fibroblasts resulted in decreased levels of p62, a protein
specifically degraded by the autophagy pathway (51) (data not shown). Together these
results indicate that the cell lines used for subsequent experiments are capable of being
induced to functional autophagy by influenza infection and that our methods of silencing
this process are effective.
Autophagy can contribute to the presentation of endogenous antigens on MHC class
II molecules. We next determined whether autophagy can deliver endogenous antigens
for epitope presentation to CD4+ T cells as has been previously described (8, 23, 34, 45,
50, 53). To this end, we appended the classically presented H2-IEd restricted Site 1 (S1)
epitope of influenza hemagglutinin, which appears to have innate resistance to endocytic
proteases (3, 11) to two proteins that have been well described to localize naturally to the
autophagosome. S1-conjugated neomycin phosphotransferase (C-terminal attachment) or
S1-conjugated LC3B (N-terminal attachment) were transiently transfected into B6-IEd
fibroblasts and S1 presentation was assessed using S1-specific T cell hybridomas. As
shown in Figure 3, the S1 epitope was presented efficiently from both constructs
compared to mock transfected controls. T cell stimulation was enhanced when cells
expressing either construct were treated with rapamycin, consistent with an autophagy
dependent mechanism of presentation. The more dramatic response of the S1LC3

construct is likely due to LC3B being a specific component of the autophagy pathway
whereas NeoS1 is an autophagy substrate that may be less efficiently incorporated into
the autophagosome.
Overnight treatment of S1LC3 expressing cells with the chemical inhibitors of
autophagy 3MA or wortmannin significantly reduced the presentation of the S1 epitope
from B6-IEd fibroblasts (Fig. 4a). 3MA treatment inhibited S1 presentation to a greater
extent than wortmannin; however it was also observed to be more toxic to the cells in
culture (data not shown). Atg7 siRNA transfection of B6IEd cells stably expressing
S1LC3 also resulted in decreased S1 presentation compared to control siRNA transfected
cells (Fig. 4b). Additionally, we mutated the glycine at residue 120 of LC3 to an
alanine, which prevents LC3 conversion (25). This substantially reduced S1 presentation
from the fusion protein (see Fig. S1 in the supplemental material).
Establishing a system to assess the contribution of autophagy to the CD4+ T cell
response to influenza. To determine the contribution of autophagy to the in vivo
influenza-specific CD4+ T cell responses, we elected to use an assay that we previously
developed for assessing the influence of proteasome activity on the magnitude of the
CD4+ T cell response (66). This involved infection of wild-type mice and analyzing the
resulting CD4+ T cell response with an interferon-γ ELISpot in which influenza-infected
stimulator cells were treated with or without proteasome inhibitor. The difference in spot
number reflected the number of T cells specific for proteasome-dependent epitopes. Even
if proteasome deficient mice had been available, we would have chosen this
configuration rather than comparing responses in infected wild-type and knockout mice.
Our rationale was that the limited homeostatic space might have allowed greater and

lesser quantities of naïve T cells in the wild-type and knockout mice to expand to the
same absolute numbers. Thus, although mice have been generated with autophagy
deficiencies in certain cell types (34), we opted to dissect the response that occurs in
wild-type mice. Aiding this decision was the report that DCs from these knockout mice
appear to be impaired in exogenous antigen processing as well (34). To ensure that the
assay was sufficiently sensitive, we determined the change in the responding T cell
population that can be statistically detected. BALB/c mice were primed with either PR8
or B-Lee influenza viruses which are immunologically distinct. Ten days after priming,
CD4+ T cells were isolated from the spleens, mixed in different proportions and cultured
with L-IEd fibroblasts infected with either PR8 or B-Lee virus. Antigen specific CD4+ T
cell responses above background were detected when 10% of the total T cell population
was specific for the restimulating virus (see Fig. S2 in the supplemental material).
Also in preparation for analysis of the in vivo response, we constructed a positive
control adenovirus that expresses S1LC3 (Adeno-S1LC3). We immunized mice
intranasally with live PR8 virus and at least 10 days after immunization isolated CD4+ T
cells from the spleen via negative selection. Under these conditions, the S1 epitope is
immunodominant (21). The CD4+ T cells isolated from influenza primed mice were
cultured with siRNA transfected L-IEd fibroblasts infected with Adeno-S1LC3 virus.
Because only S1 is shared between the two viruses, only S1 specific T cells respond in
the assay. Atg7 knockdown in Adeno-S1LC3 infected L-IEd fibroblasts significantly
reduced the number of responding CD4+ T cells in an IFN-γ ELISpot assay (Fig. 4c). A
decrease in S1 specific T cell activation in an in vitro T hybridoma assay (Fig. 4d) was
also observed. Together, these results demonstrate that ELISpot assays are capable of

detecting with considerable sensitivity a CD4+ T cell population specific for autophagydependent epitopes expressed in the context of a viral infection.
Proteasomal activity, but not autophagy, contributes to global MHC class II
restricted presentation in an influenza virus infection. Having observed that influenza
does induce functional autophagy, and having validated various aspects of our approach,
we asked whether macroautophagy plays an appreciable role in the global CD4+ T cell
response to this complex antigen. L-IEd or B6-IEd fibroblasts were transfected with
control or Atg7 specific siRNA, infected with live PR8 virus, and cultured with purified
CD4+ T cells from influenza primed mice in IFN-γ ELISpot assays. Under these
conditions, more than 90% of the restimulating fibroblasts were infected with PR8 virus
(see Fig S3 in the supplemental material). If macroautophagy plays a major role in the
generation of MHC class II-restricted influenza-derived epitopes in vivo, then CD4+ T
cells that recognize autophagy-dependent epitopes will have been induced, and inhibition
of this pathway should result in a decrease in the number of responding CD4+ T cells in
the ELISpot assay. However, despite validation of knockdown (Fig. 4c) and sensitivity of
the assay, Atg7 siRNA had no detectable effect on the number of responding CD4+ T
cells (Fig. 5a-d). Similar results were obtained utilizing intraperiotenal or intranasal
routes of immunization and also when limiting doses of influenza were used both for
priming and for infection of the antigen presenting cells (Fig 5a vs. c and 5b vs. d. and
data not shown). When utilized as stimulators in the ELISpot assay, the A20 B cell
lymphoma line, the Raw264.7 macrophage cell line, (see Fig. S4 in the supplementary
material) and fibroblasts deficient in the autophagy protein Atg5 (data not shown) yielded
similar results.

To address the possibility that experimental conditions bias the response towards
exogenously processed epitopes, thereby masking contributions by endogenously
presented epitopes, stimulators were pulsed with equivalent doses of infectious or UVinactivated influenza virus. An appreciably greater number of CD4+ T cells were
activated in response to live virus stimulation, indicating that endogenous epitopes are
well-represented in the ELISpot assays (See Fig S5 in the supplemental material). We
further investigated possible masking effects by eliminating the response to the
glycoproteins (HA and NA) which are major targets of the CD4+ T cell response (below),
and which, by virtue of their membrane tethering, are not expected to be substrates for
autophagy. This was accomplished by stimulating PR8 (H1N1)-primed CD4+ T cells in
the ELISpot assay with JAP (H2N2)-infected L-IEd fibroblasts, thereby restricting the
response to the untethered internal and non-structural proteins that are virtually identical
in all influenza A viruses. This heterologous restimulation reduces the total number of
responding T cells by ~ 50% compared to PR8 restimulation (see Fig S5 in the
supplemental material). However, autophagy inhibition using Atg7 siRNA does not
significantly reduce the number of responding T cells after JAP restimulation. Thus, a
substantial portion of the CD4+ T cell response is directed against internal proteins whose
epitopes are produced principally, if not completely, by processes other than autophagy.
DCs play a major role in priming both class I- and class II- restricted responses in
vivo and it was possible that DCs are more active in macroautophagy than the ELISpot
stimulator cells that had been tested and/or are distinct in their selection of autophagy
substrates. To address this concern, BMDCs were transduced with the shRNA retroviral
vector LMP or LMP encoding an shRNA for Atg7. 48-72 hours after transduction,

BMDCs were sorted for high GFP expression, infected with PR8 virus, and cultured with
CD4+ T cells purified from influenza virus infected mice in an IFN-γ ELISpot assay.
Flow cytometry confirmed synthesis of viral proteins within DCs pulsed with infectious
virus but not equivalent amounts of UV inactivated virus, indicating availability of
endogenous antigens (see Fig S3 in the supplemental material and data not shown).
Furthermore, stimulation of influenza specific CD4+ T cells with DCs infected with live
virus resulted in higher amounts of T cell activation than when UV inactivated virus was
used (data not shown), again indicating that the a substantial portion of the class II
response is directed against endogenous epitopes. Knockdown of Atg7 in GFPhi cells was
substantial (Fig 6A) and this resulted in functionally impaired autophagy as reflected by
p62 accumulation (Fig 6B). As with all the other cell types tested,, these primary DCs
demonstrated no significant contribution of the macroautophagy pathway to in vivo CD4+
T cell activation (Fig 6C). Importantly, in contrast to Atg5 deficient DCs (34), the
presentation of exogenous antigens in our system was not affected (see Fig S6 A,B in
supplemental material).
As previously reported (66), treatment of stimulatory APCs with the proteasome
inhibitor epoxomicin resulted in a significant decrease in the number of CD4+ T cells
responding in the ELISpot assay (Fig. 7a, b). This was not due to non-specific effects of
epoxomicin as presentation of synthetic peptide and the classically presented S1 epitope
were not affected. Additionally, while inhibition of protein translation is a potential offtarget effect of proteasome inhibitors, production of influenza proteins was only
marginally inhibited (see Fig. S7 in the supplemental material). In order to further
substantiate the contribution of proteasome-dependent processing and to obtain a closer

comparison with our autophagy related results we carried out siRNA knockdown of Rpt2,
an ATPase subunit of the 19S regulatory cap of the proteasome (54). The impact on the
ELISpot assay was comparable to that of epoxomicin treatment (without an effect on
protein synthesis), while siRNA inhibition of Atg7again had no effect (Fig. 7c,d).
In summary, although we were able to demonstrate autophagy dependent
presentation of individual epitopes, both after transfection and viral infection, we were
unable to detect a significant contribution of this pathway to the global presentation of
class II restricted epitopes derived from influenza virus infection. At the same time, we
did observe a significant contribution of the proteasome dependent pathway to the global
class II-restricted response using two different approaches. These results reinforce the
notion that, at least for influenza virus, the majority of the endogenous epitopes presented
on MHC class II are processed via proteasome-dependent pathway(s).

DISCUSSION
With recent work highlighting the potential for macroautophagy to orchestrate
endogenous MHC class II-restricted presentation of individual antigens(16, 35, 44, 45,
50, 60), our goal was to determine the role in the CD4+ T cell response to a complex
pathogen, specifically influenza. We focused upon this virus due to our previous
elucidation of a proteasome-dependent endogenous pathway that is responsible for a
substantial portion of the class II-restricted response to influenza infection (66).
Considering the large contribution that the classical exogenous pathway also makes to the
response, we wondered if there would be sufficient opportunity for another major
pathway. Before addressing this central question, preliminary work in three general areas
was required to validate both the relevance of studying autophagy in the context of an
influenza infection and the experimental system that we had selected.
First, although influenza virus infection has been shown to induce LC3
conversion in a number of cell lines, it remains unclear whether functional autophagy,
resulting in membrane fusion with active lysosomes, is stimulated (15, 33, 73). It has
been reported that influenza infection of human lung epithelial cells prevents
autophagosomes from fusing with lysosomes (15) with the viral M2 protein acting as an
inhibitor of Beclin-1, a key protein in the autophagy pathway. However, others have
concluded that functional autophagy, as measured by the degradation of the autophagy
substrate p62, does occur in the face of influenza infection (33). The discrepancies may
be due to the cell types and/or the influenza strains that were utilized. As assessed by
both GFP-LC3 and p62 degradation, we observed that influenza virus infection does

induce functional macroautophagy in several different cell types, including primary DCs,
with no detectable block in the pathway.
Second, using a standard approach in the field, we ascertained our ability to
observe macroautophagy dependent antigen processing by tracking presentation of an
individual epitope (2, 35, 45, 50). Appending the S1 epitope onto neomycin
phosphotransferase or LC3B and expressing the constructs via transfection resulted in
autophagy dependent presentation that could be enhanced by inducing autophagy with
rapamycin or significantly decreased by chemical and genetic inhibition of the autophagy
pathway. We also constructed an adenovirus expressing the S1LC3 fusion protein and
obtained similar results.
Third, we utilized a recombinant adenovirus to validate the ELISpot assay that
was subsequently used to assess the global contribution of autophagy. Results
demonstrated that dependence of a polyclonal T cell population on functionally active
autophagy within the APC could be readily appreciated. Because this assay represented a
best case scenario in which all of the responding T cells were specific for the autophagydependent epitope, we carried out additional assays with heterologous influenza viruses,
which confirmed that even minor populations within the pool of primed CD4+ T cells
(≤10%) could be detected.
With the general framework of the assay having been validated, analyses could
have been carried out in two general ways: 1) Infection of wild-type and autophagy
deficient mice (which have autophagy defects in only certain cell types), and subsequent
determination of the differences in the CD4+ T cell responses, or 2) infection of wild-type

mice only, with subsequent identification of the autophagy-dependent component. We
chose the latter for two reasons. First, despite possible differences in precursor
frequencies, CD4+ T cells in wild-type and mutant mice might have expanded to the same
absolute numbers requiring us to analyze differences by less meaningful criteria, such as
T cell receptor diversity. Furthermore, because multiple subsets of antigen presenting
cells can initiate an immune response, the selective autophagy knockout system that is
currently available would complicate interpretation. In fact, mice that lack the Atg7
gene only in the hematopoietic stem cell compartment (either due to conditional knockout
or reconstitution of an irradiated wild-type mouse withAtg7 deficient bone marrow)
display reduced numbers of multiple immune cell subsets and die within weeks
following elimination of this protein(43). Furthermore, recent analysis of Atg5 deficient
DCs from the knockout mice indicates a deficiency in exogenous antigen processing (34).
Our results demonstrate that short-term knockdown of autophagy, in contrast, does not
have this effect.
Having carried out these preliminary steps, we asked whether macroautophagy
plays a major role in the generation of epitopes during influenza virus infection. Despite
potent induction of functional autophagy by influenza virus infection and a sufficiently
sensitive assay, we detected no significant contribution of this pathway to the global
CD4+ T cell response to influenza virus. This was true of all antigen presenting cell types
tested including primary DCs and also when the assay was restricted to the internal and
non-structural proteins of the virus. In contrast, as previously reported (66) a substantial
portion of the CD4+ T cell response was observed to be proteasome-dependent by two

independent methods for modulating proteasome activity (chemical inhibition and siRNA
treatment).
Several factors may limit the utility of autophagy for class II-restricted epitope
generation. Although largely considered a nonselective pathway of protein degradation,
recent data suggest that efficient delivery of individual soluble proteins to the
autophagosomes is dependent upon a specific recognition mechanism (27, 29, 46). In
agreement with this, the S1 epitope is more robustly presented from the S1LC3 construct,
which is directly targeted to the autophagy pathway via LC3B, compared to the NeoS1
construct, which is likely targeted by less selective mechanisms. It seems unlikely that
individual viral proteins would self target to this compartment, as has been reported in
some cases (69), unless it were advantageous. Both poliovirus and rhinovirus induce the
formation of double membrane autophagosomes to facilitate replication and autophagy
inhibition via siRNA was observed to decrease the amount of poliovirus released from
infected cells. Indeed, conditions necessary for processing are likely absent since induced
autophagosomes are not mobile and presumably do not fuse efficiently with the late
endosome compartment (65). Likewise, hepatitis C virus induces autophagy to initiate
the early stages of viral replication (9, 10, 64) but the degradation of autophagy
substrates, including p62, is blocked (63).
Once captured by the autophagosome, an epitope must survive in the highly
proteolytic environment of the late endosome/lysosome. This may be a losing prospect in
many cases. Enhanced proteolytic activity has been reported to be generally detrimental
to antigen presentation, consistent with the idea that proteases and empty class II
molecules compete for access to unfolded proteins (7, 59) . What is more, autophagy

inhibition via siRNA has been reported to reduce cathepsin activity in the late endosome
(34), suggesting that fusion of the autophagosome with the endosomal compartment may
create an even more aggressive environment. We have previously reported on the
negative impact of heightened proteolysis. Presentation of the hemagglutinin-based S3
epitope from exogenous sources of PR8 is enhanced up to ten-fold when endosomal
cathepsins are inhibited (3), while the NA79 epitopes appears to be so susceptible to
endosomal proteases that presentation from exogenous virus is undetectable in most cases
(11, 66). In contrast to S1, neither of these epitopes was presented when appended to
neomycin phosphotransferase with or without rapamycin treatment (data not shown),
suggesting that they are immediately destroyed upon delivery to the autophagosome.
Thus, only those class II-restricted epitopes that are sufficiently resistant to
endolysosomal proteolysis, may be candidates for autophagy mediated presentation.
We cannot rule out the possibility that there is a small autophagy-dependent
fraction of the class II-restricted influenza response that is below the detection limit of
our assays. In our system, we determined the sensitivity of the ELISpot assay to detect
antigen specific T cells to be <10%, suggesting that if autophagy does play a role in the
class II response, the contribution is minimal. In addition we cannot discount the
possibility that epitopes are generated via parallel pathways such that inhibition of
autophagy would shift the substrate to other processing routes.
In preliminary experiments the global class II responses to vaccinia and
adenovirus infections are also not substantially altered by inhibition of autophagy (J.D.C.
unpublished observations). We are, nevertheless, cautious about generalizing these
findings to other viruses. All three of the viruses that have been tested mediate acute and

limiting infections in mice. In contrast, herpes viruses such as EBV are generally chronic
and evasion from CD8+ T cell recognition appears to be a major priority (5). The EBNA1 protein contributes directly to this effort by blocking proteasomal degradation and
subsequent MHC class I restricted presentation via an N-terminal Gly-Ala repeat (36,
37). Other herpes viruses encode proteins with similar functions (31, 71). Inhibition of
the proteasome induces aggregate formation which may shift the balance of global
protein degradation towards the autophagy pathway (28, 32, 68). Thus similar analyses
of viruses with fundamentally different replication strategies are warranted
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